$303 Million is the total value of SV Health Investors, LLC's 5 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 33.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
OCUL | OCULAR THERAPEUTIX INC | $108,570,000 | +78.5% | 2,585,607 | 0.0% | 35.88% | +18.2% | |
OPHT | Sell | OPHTHOTECH CORP | $95,533,000 | -18.8% | 2,053,143 | -21.7% | 31.57% | -46.2% |
ENTL | New | ENTELLUS MED INC | $76,421,000 | – | 3,489,533 | +100.0% | 25.25% | – |
TRXC | TRANSENTERIX INC | $22,112,000 | +0.7% | 7,546,692 | 0.0% | 7.31% | -33.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SVLSF IV, LLC #1
- SV Life Sciences Fund IV (GP), L.P. #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
TRANSENTERIX, INC. | 27 | Q4 2020 | 24.0% |
OCULAR THERAPEUTIX, INC. | 24 | Q2 2020 | 35.9% |
KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 31.0% |
DECIPHERA PHARMACEUTICALS INC | 17 | Q3 2021 | 31.0% |
CATABASIS PHARMACEUTICALS, INC. | 15 | Q4 2018 | 18.2% |
X4 PHARMACEUTICALS INC | 15 | Q3 2022 | 3.2% |
BICYCLE THERAPEUTICS PLC | 14 | Q3 2022 | 65.4% |
SUTRO BIOPHARMA INC | 14 | Q4 2021 | 19.1% |
ENTELLUS MED INC | 12 | Q4 2017 | 64.4% |
AVROBIO INC | 12 | Q1 2021 | 41.6% |
View SV Health Investors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2022-11-07 |
13F-HR | 2022-08-12 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-11 |
13F-HR | 2021-11-15 |
13F-HR | 2021-08-16 |
13F-HR | 2021-05-17 |
13F-HR | 2021-02-16 |
13F-HR | 2020-11-12 |
13F-HR | 2020-08-14 |
View SV Health Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.